India’s contact tracing app integrates with ABDM


Aarogya Setu, India’s official national contact tracing app, is the latest app to connect to the Ayushman Bharat Health Account, the health identification component of the Ayushman Bharat Digital Mission.

Developed by the National Computing Center of the Ministry of Electronics and Information Technology (MeitY), the mobile app not only tracks COVID-19 cases but also provides users with related information to COVID-19, such as protocol updates and services. It uses Bluetooth technology and taps into real-time location data to determine a user’s risk of being exposed to a nearby COVID-19 case.

The app, which launched in April 2020, is available on Android and iOS devices.


This integration allows approximately 214 million users of the national contact tracing app to create their unique 14-digit ABHA. Health ID allows users to link their existing and new medical records to their ABHA and share them with healthcare providers.

National Health Authority CEO Dr. Ram Sewak Sharma said that with the integration, “we will now be able to bring the benefits of ABDM to Aarogya Setu users and enable them to to join the digital health ecosystem with their consent”.

Later, the app will be updated to show an ABHA user’s health record.


Aarogya Setu adds to the growing number of mobile health apps that integrate with the ABHA. Earlier this month, personal health records app DRiefcase and EMR platform Docon Technologies received government approval to connect to the ABHA.

Last year, in March, the app integrated with the CoWIN portal, allowing users to book their COVID-19 vaccinations through the app.

Following the findings of independent reviews that the app poses security risks, MeitY has released the source code of the Aarogya Setu app to the public in order to promote transparency and ensure the security and integrity of the app. . It also launched a bug bounty program, seeking help from the developer community to spot vulnerabilities or improvements to the app’s code.


Comments are closed.